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ABSTRACT
A simple and reproducible reversed-phase ion-pair high performance liquid chromatography (HPLC) method using isocratic
elution with UV absorbance detection was developed and validated for the simultaneous determination of carboxylate (C) and
lactone (L) forms of SN-38 (active metabolite of irinotecan) in nanoparticles (NPs). Reversed phase (RP) chromatography was
performed on a C18 column with an ion-pair solution, KH 2PO4 buffer solution and acetonitrile, under a mobile phase 30:30:40 (v/v)
and at a flow rate of 1 mL/min. Detection was performed at 265 nm and sharp peaks were obtained for C and L forms of SN-38 at
retention times of 2.9 ± 0.01 and 5.1 ± 0.01 min respectively. Linear regression analysis data for the calibration plot showed a good
linear relationship between response and concentration in the range of 4 to 100 µg/mL; the regression coefficient was 0.9999 for L
form and 0.9998 for C form. The optimized method showed good performance in terms of specificity, linearity, detection and quantitation limits, precision and accuracy in accordance with the International Conference on Harmonization (ICH) Q2 (R1) guidelines.
This assay was demonstrated to be applicable for routine quantitation of SN-38 in PLGA NPs.
Key words: SN-38, irinotecan, nanoparticles, ion-pair, HPLC

INTRODUCTION
Camptothecin (CPT) is a natural, water-insoluble
quinoline alkaloid produced by an Asian tree, Camptotheca acuminata [native to China and Tibet](1). Camptothecin has been modified to create a host of other
anti-cancer drugs, including irinotecan (CPT-11). SN-38
(7-ethyl-10-hydroxycamptothecin), the active metabolite
of irinotecan, is 100-1000 folds more cytotoxic than irinotecan against many tumor cell lines. The schematic drawing of SN-38, irinotecan and CPT is shown in Figure 1(1-3).
Only a small proportion (2-8%) of irinotecan is converted
to SN-38(2,3), and so a large dosage of irinotecan is needed
to obtain therapeutic efficacy. Furthermore, the conversion of irinotecan to SN-38 is extremely variable and thus
* Author for correspondence. Fax: +98-21-66959055;
Email:dinarvand@tums.ac.ir

causes toxicity risks for the patients(4,5). Nevertheless, the
delivery of SN-38 is wholly challenging due to instability
and low water solubility (6,7). Nanoparticle (NP) technology may provide a solution for such problems and promote
a sustained chemotherapy. Drugs incorporated into NPs
have also shown increased activity(8). In our previous
study a novel and well-characterized poly lactide-co-glycolide (PLGA) NPs loaded SN-38 was developed to overcome these problems and provided a mechanism of direct
delivery of SN-38 without in vivo enzymetic conversion(3).
Camptothecins and related analogues contain a closed
-hydroxy--lactone ring (L form) that can undergo reversible hydrolysis to form the open-ring form (C form). In
vitro and in vivo pharmacological study showed that the
hydroxy acid is a less potent inhibitor of topoisomerase
I and a much less potent antitumor agent with much
stronger toxic effects(9,10). Chemical structures and equilibrium reaction between the L and C forms of SN-38
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Figure 1. Schematic structure of SN-38, irinotecan and CPT.
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Figure 2. Schematic structure of lactone and carboxylate forms of SN-38.

are shown in Figure 2. Analytical procedures determining camptothecin derivatives could be classified in two
groups: methods quantifying total concentration of these
drugs and methods that discriminate between the L and
C forms. Since L is the active form of these anticancer
agents, discriminating between L and C forms appears to
be an aim to evaluate the pharmacokinetics and pharmacodynamics of these compounds and in pharmaceutical
development(11,12). The method presented here identifies
the L and C forms of SN-38 and determines concentration
of SN-38 in NPs. Several methods have been published for
the determination of C and L forms of SN-38 in several
matrix (plasma, microsomal extracts, and liposomes,
etc.), including liquid chromatography-tandem mass spectrometry (LC-MS/MS), high performance liquid chromatography (HPLC) with ultraviolet (UV) or fluorescent
detector (13-19). However, no analytical method has been
validated for determination of SN-38 loaded PLGA NPs.

To date, most techniques were limited to determine the total concentrations of two forms of SN-38 by
transferring carboxylate forms to lactone forms through
acidification of the sample (16) or by transferring lactone
forms to carboxylate forms through basification of the
sample (18). Some methods were able to determine the
carboxylate forms of CPT-11 and SN-38 in plasma by
subtracting lactone form from the total form with appropriate process to stop the conversion of lactone form to
carboxylate form(16). However, these methods needed
several different HPLC conditions for each sample to
determine the lactone form and total form separately.
Some methods could separate lactone and carboxylate
forms simultaneously by gradient elution(17,21). Although
these methods had similar limit of detection (LOD) or
limit of quantitation (LOQ), or similar retention time in
comparison with our method, most of them used fluorescence detector (15-19). We used UV detector in our method
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because it is more common than fluorescence detector.
As analysis of SN-38 in NPs is necessary to pass in
vitro or in vivo assay test, valuation of a new formulation
of the SN-38 like measuring encapsulation efficiency, or
release of particulate drug delivery systems containing
SN-38, a simple, reproducible and cost-effective analysis method is important. Additionally, proper sample
handling should be adopted to avoid the conversion
between these two forms.
The development of this chromatographic method
suitable to the quality control of NP formulation is a
significant improvement in terms of simple steps and
sensitivity. The aim of the presented work was to introduce a simple, sensitive, compendial and rapid isocratic
HPLC method for the simultaneous determination of
the L and C forms of SN-38 loaded PLGA NPs and to
continue formulation development in vitro and in vivo.

MATERIALS AND METHODS

III. Identification
The identification was performed as a part of assay.
The retention time of the major peak in the chromatogram of the test solution in three sequential replicate of
injections was compared to that of standard solution. The
same retention time of test and standard identified the
same analyte.
IV. Ion-pair Solution (Solution A)
To prepare solution A, about 1.2 g of octane-1sulfonic acid sodium salt was transferred to a suitable
container and dissolved in 500 mL of water.
V. Solution B
To prepare solution B, 13.6 g of potassium dihydrogen phosphate (KH 2PO 4) was transferred to a suitable
container and dissolved in 500 mL of water.

I. Materials

VI. Mobile Phase

SN-38 was obtained from ABATRA Co., Shaanxi,
China. PLGA (Resomer 504) was purchased from Boehringer Ingelheim, Germany. Poly vinyl alcohol (PVA) (MW
22,000) was purchased from Sigma-Aldrich (St. Louis,
MO, USA). The ion-pairing reagent octane - 1- sulfonic
acid sodium salt was purchased from Sigma Chemical
(St. Louis, MO, USA). Dichloromethane (DCM) (analytical grade) and acetonitrile (HPLC grade) were purchased
from Merck (Darmstadt, Germany). The Purified water
was prepared using Milli-Q water system (Millipore Corp,
Bedford, MA, USA). All other chemicals used were of
analytical grade.

Mobile phase consisted of a suitable filtered and
degassed mixture of Ion-pair solution, solution B and
acetonitrile (30:30:40, v/v/v). Then pH of mixture was
adjusted to 3.0 with phosphoric acid.

II. Preparation of SN-38 NPs
The SN-38 loaded NPs were fabricated by emulsification/solvent evaporation method(3,20). In brief, 10
mg of PLGA 50:50 and 2 mg of SN-38 were added to
DCM, which was stirred to ensure that all materials were
dissolved. The dispersed phase was slowly dropped into
aqueous solution of PVA (pH was adjusted to 3 by 0.1N
HCl) using a high-speed homogenizer (ultra-turrax IKA,
Wilmington, MA, USA) at 24,000 rpm. The formed o/w
emulsion was gently stirred at room temperature by a
magnetic stirrer for 3-5 hours to evaporate the organic
solvent. The NPs were recovered by centrifuging (21,000
g, 30 min, Sigma 3k30, Germany), followed by washing
thrice with deionised water. The produced suspension
was freeze dried for 48 hours (Lyotrap plus, LYE Scientific Ltd, Oldham, UK) to obtain a fine powder of NPs.
NPs without SN-38 were prepared by the same procedure.
Freeze dried NPs were stored in a sealed glass vial and
placed in desiccators kept at 4°C.

VII. Preparation of Stock and Standard Solutions
An accurately weighed quantity of SN-38 standard
(5 mg) was transferred into a 50-mL volumetric flask
and dissolved in acetonitrile to obtain a stock standard
solution with concentration of 100 µg/mL. Then other
concentrations of standard solution for calibration curve
were prepared by dilution of stock standard solution in a
suitable volumetric flask with acetonitrile for L form and
acetonitril-water (50:50, v/v) (pH of solution should be
adjusted to10) for C form. Equal volumes (20 µL) of each
standard solution and the test solution were injected into
the chromatograph.
VIII. Linearity and Range (Calibration Curve)
The calibration curves were constructed by plotting
the peak area ratio of the analytes over standard versus
the concentrations spiked. Solutions of different concentrations (4-100 µg/mL) for construction of calibration
plots were prepared from the stock solution as described
above. The solutions of 4, 10, 30, 40, 50, 80 and 100 µg/
mL of SN-38 were prepared by spiking of SN-38 L and C
form at seven aforementioned concentrations.
IX. Assay Preparation
An accurately weighed portion of the freeze dried
powder, presumably at a concentration similar to that
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of the standard solution of SN-38, was transferred to a
suitable volumetric f lask, dissolved in and diluted with
acetonitrile to volume, mixed and filtered to obtain a
solution with concentration of the drug in the range of
linearity previously described. The quantity of SN-38 in
NPs (in mg), was calculated by the following formula:
100C (r t / r s)
in which C is the concentration of SN-38 reference
standard in standard solution (in mg/mL); and r t and rs
are the SN-38 peak responses (Peak area) of test and standard solution, respectively.
X. Chromatographic System
In this study, SN-38 was analyzed by a Knauer
HPLC system (Germany) consisted of a model Wellchrom
K-1001 pump, a model Rheodyne 7125 injector and a
model K 2501 UV detector connected to a model Eurochrom 2000 integrator. The separation was performed
using a C18 analytical column (Base deactivated packing H.P. 25 cm × 0.46 cm internal diameter, pore size
5 mm, Capital HPLC, UK) at 30°C using mobile phase
(as mentioned above) at a ﬂow rate of 1 mL/min. Each
sample was injected into the column at a constant volume
of 20 μL for an analysis run of 10 min (rapid). The UV
detection wavelength was set at 265 nm for the chromatographic analyses of SN-38 NPs, respectively. System suitability solution chromatographed and recorded the peak
responses (peak areas) as directed for procedure. The
analytical column theoretical plate number and tailing
factor of the analytes under different chromatographic
conditions were calculated using USP methods (21).

min. At predetermined time intervals, the tubes were
taken out of the water bath and centrifuged at 21,000 g
for 30 min and the entire supernatant were collected for
further SN-38 analysis by HPLC. Afterwards, the precipitated particles were re-suspended in 10 mL of fresh
buffer (in order to maintain sink conditions) and put back
into the shaker to continue the release measurement. The
HPLC method used was the same as described above.
XIII. Method Validation
Validation of an analytical procedure is the process
by which it is established, by laboratory studies, that
the performance characteristics of the procedure meet
the requirements for the intended analytical applications (21). Typical analytical performance characteristics
for the validation of procedures according to ICH Q2(R1)
guidelines described in this document include accuracy, precision, specificity, detection limit, quantitation
limit, linearity, range, robustness and system suitability
test (22,23).
XIV. Stability of Drug Solution
Stability of the drug solution was determined based
on the retention time and (%) recovery of SN-38 solution (4, 40 and 100 μg/mL). The drug solution was kept
at room temperature (around 25°C) for three consecutive
days.

RESULTS AND DISCUSSION

XI. Drug Encapsulation Efficiency

I. Optimization of the Chromatographic Method

The drug entrapped in the NPs was determined
in triplicate by HPLC. A 10-mg sample of NPs powder
was dissolved in 10 mL of acetonitrile. The solution was
filtered using RC- 45/25 CHROMAFIL with pore size of
0.45 µm, Ø: 25 mm (MACHERY- NAGEL, Germany) into
a vial. An aliquot of 20 µL was analyzed by the HPLC
system to detect the SN38 concentration. The encapsulation efficiency of SN-38 was obtained as the mass ratio
between the amount of SN-38 incorporated in NPs and
that used in the NP preparation.

An optimized reversed-phase HPLC method for the
assessment of SN-38 in association with nanoparticulate carriers has been proposed. This study was exploited to provide a simple procedure with increasing chromatographic peak resolution, reduced running time and
low cost of analysis. All these factors contribute to the
establishment of an analytical method which permits the
analysis of a large series of samples and prevents possible degradation due to long analysis time. The relatively
symmetrical SN-38 peak has a retention time of 5.11 min.
The chromatographic behavior of SN-38 was ﬁrst studied using the method reported by Xuan et al.(13). In this
study, the SN-38 standard (40 µg/mL) was analyzed on
a Nucleosil C18 (Phenomenex, 4.0 mm × 250 mm, 5 m)
analytical column, NaH 2PO 4 (pH 3.1, 25 mM) and acetonitrile (50:50, v/v) mobile phase at a ﬂow rate of 1 mL/
min. It was found that retention times of C and L forms
of SN-38 were very close and shifted as much as 5%
among 6 replicate injections so that the base line separation was not completed when Nucleosil C18 was used.
In order to prevent the retention time shift and increase
the peak resolution of these two forms, changes in the

XII. In vitro Release Study
The release rate of SN-38 from the NPs was
measured in phosphate buffered solution (pH 7.4) at 37°C
by HPLC in triplicate. Briefly, 10 mg of NPs powder was
poured in screw-capped tubes and dispersed in 10 mL of
phosphate buffer solution (PBS). The pH of the monobasic potassium phosphate solution was adjusted by 0.2 N
NaOH. Then the tubes were placed in an orbital shaker
bath (WB14 Memmert, Schwabach, Germany), which was
maintained at 37°C and shaken horizontally at 90 cycles/
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the retention times of these two forms are less than 20
min, it can be deduced that the real percentage of them
has been calculated. A typical chromatogram for the
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Figure 3. Representative HPLC chromatogram for SN-38 lactone and
carboxylate form separation with resolution of 5.86 ± 0.12 (n = 3).
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component of mobile phase were further investigated. In
this study attempts to separate SN-38 L by varying the
acetonitrile composition and in pH of the running buffer
of the mobile phase in order from the C form interferences did not provide much improvement. It was found that
increasing ion-pair agent and reducing buffer ratio led to
minimal shift in retention time but significantly improved
peak resolution. Hence, adding ion-pairing reagent
octane-1-sulfonic acid sodium salt to the mobile phase
changes the polarity gap between the two analytes, so as
to improve chromatographic separation(24). In the present
study, we have chosen a mobile phase with 0.1 M potassium dihydrogen phosphate containing acetonitril and
ion-pair agent at pH 3 which resulted in efﬁcient separation between compounds with suitable retention time.
The potassium dihydrogen phosphate buffer used in the
mobile phase could control the pH value and ion strength,
while the ion-paring agent octane sulphonic acid sodium
salt would change the afﬁnity of the C forms to column
C18 particles, which would facilitate their separation.
As for other camptothecin class of compounds,
SN-38 undergoes pH-dependent reversible hydrolysis
of the active α-hydroxy-δ-lactone ring to form an inactive carboxylate derivative in aqueous solutions (PH ≥
7) and plasma (13-19). The L ring of SN-38 is unstable and
converts to an open-ring C form under basic conditions.
A survey of L-C structural conversion of SN-38 under
the different pH conditions was performed using the
defined ion-pair HPLC method to determine the desirable
mobile phase pH with minimal structural conversion. As
shown in Figure 3, 16.67% of SN-38 existed in C form
and 83.3% in L form when pH of the diluents (water/
acetonitrile = 50:50, v/v) was kept at 7. When pH of the
diluent was changed to 10, about 100% of SN-38 was in
C form (Figure 4). Once pH of the diluent was adjusted
to 3, almost all the open C form of SN-38 converted to L
structure. This pH-dependent structural conversion was
found to be reversible. Consequently, pH of mobile phase
was kept at 3 for the prevention of structural conversion
during assay. Also addition of ion-pair solution in mobile
phase increased the peak resolution and symmetric factor
of two forms of SN-38. Representative chromatograms
in Figure 3 show that C and L forms of SN-38 are base
line separated with retention time of 2.9 ± 0.01 and 5.1
± 0.01 min, respectively. As ultraviolet detection of the
compound is more common than the fluorescent detection, in this study we developed a simple and reproducible method for determination of SN-38 in NPs containing SN-38 based on UV detection and isocratic mobile
phase. This method was fast and efficient with simple
sample preparation procedure and total analytes running
time of less than 10 min, much shorter than those reported previously (about 20-30 min)(16,19). Therefore, the
risk of degradation and conversion of analytes can be
signiﬁcantly reduced during sample analysis. Note that
the conversion between C and L does not occur in the
mobile phase for at least 20 min (data not shown). Since
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Figure 4. Representative HPLC chromatogram for SN-38 carboxylate
form.
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Figure 5. (a) HPLC chromatogram obtained from PLGA nanoparticles without SN-38. (b) HPLC chromatogram obtained from SN-38 loaded
PLGA nanoparticles.

Table 1. Results of accuracy study for L form of SN-38
No.

Concentration (µg/mL)

1

4

2

3

40

100

Injection No.

Calculated × 100/Nominal (%)

1

99.34

2

101.10

3

100.46

1

102.27

2

101.94

3

102.12

1

99.34

2

98.86

3

100.52

proposed method is depicted in Figure 5b which shows
lack of C forms of SN-38 in NPs.
II. Method Validation
(I) Accuracy
In the case of the assay of a drug in a formulated
product, accuracy may be determined by application of

Average recovery (%)

RSD (%)

100.30

0.88

102.11

0.16

99.57

0,85

the analytical procedure to synthetic mixtures of the drug
product components to which known amounts of analyte
have been added within the range of the procedure (16). In
this research, accuracy was calculated as the percentage
of recovery by the assay of the known amount of SN-38
standard solution (L and C forms) which was added into
synthetic mixture or placebo of PLGA NPs. The acceptance criteria of accuracy (% recovery) should be between
95.0 and 105.0%. The SN-38 assay showed recovery
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percent of 99.57% to 102.11% with an overall average of
100.66% for L form (Table 1) and 99.86 to 100.59% with
an overall average of 100.29% for C form (Table 2). The
percent of relative standard deviation (% R.S.D.) for the
triplicate measurements at each level was less than 1.0%
which demonstrated a high level of accuracy.
(II) Precision
The precision was demonstrated at two levels: repeatability (intra-assay, intra-day or within day precision) and
intermediate precision (inter-day or between-days precision). Each level of precision was investigated by 3 sequential replicate of injections of three concentrations of 4, 40
and 100 µg/mL of SN-38 NPs (pH was adjusted 10 for C
form sample preparation). The intra- and inter-day variability or precision data were assessed by using standard
solutions (L and C forms) prepared to produce solutions of
three different concentrations of each drug. Repeatability

or intra-day precision was investigated by injecting nine
replicate samples of each samples at each concentration.
Inter-day precision were assessed by injecting the same
three samples over three consecutive days. The precision
was expressed as relative standard deviation (RSD) or
coefficient of variation (CV). The results of repeatability
and intermediate precision are shown in Table 3. The relative standard deviation (R.S.D.) values for absolute peak
areas of SN-38 in samples were less than 1.2% for both
intra-day precision and inter-day precision. These data
demonstrated acceptable precision of the method.
(III) Specificity
Speciﬁcity was investigated by using different
excipients without active substance and verifying the
absence of interferences. The chromatogram of pure
SN-38 was compared with the retention time and appearance of formulation excipients. In addition, empty NPs

Table 2. Results of accuracy study for C form of SN-38
No.

1

2

3

Concentration (µg/mL)

4

40

100

Injection No.

Calculated × 100/Nominal (%)

1

101.23

2

100.70

3

99.86

1

100.17

2

98.90

3

100.52

1

100.53

2

99.70

3

101.05

Average recovery (%)

RSD (%)

100.59

0.69

99.86

0.85

100.42

0.67

Table 3. The precision of the method in the range studied
Precision
Repeatability
(intra-day
precision)

Intermediate
precision
(inter-day
precision)

Acceptance Criteria
The RSD of peak areas
and retention time of
SN-38 in the AVSS
should not be more
than 2%.

Concentration
(µg/mL)

RSD of peak area
for L form

RSD of tR
for L form

RSD of peak area
for C form

RSD of tR
for C form

4

0.83

0.88

0.91

0.40

40

0.71

0.56

0.70

1.1

100

0.45

0.44

0.49

0.94

4

0.92

0.85

0.79

1.06

40

0.64

0.78

0.63

0.82

100

0.54

0.36

0.49

0.69

RSD: Relative Standard Deviation; AVSS: Analytical Validation Standard Solution
Acceptance Criteria: The RSD of peak areas and retention time of SN-38 in the AVSS should not be more than 2%.
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were prepared in the same way for SN-38 NPs. The main
purpose was to detect any retention peak due to single or
combination of isolate polymer. No peak was observed in
the chromatogram of each excipient and empty NPs at the
retention time of SN-38 NPs (L form) (Figure 5a and 5b)
and C form (Figure 4). Our result indicates specificity of
the method.
(IV) Limits of Detection and Quantitation

filter and delivered at 1 mL/min for column equilibration; the baseline was monitored continuously during
this process. It was found that in the concentration range,
the detector response of SN-38 was linear with a correlation coefficient greater than 0.999 for L form and 0.9998
for C form.
(VI) Robustness

The LOD was determined by analyzing SN-38 standards in six successive injections at different concentration levels in decreasing order until signal to noise (S/N)
ratio reached about 3. The LOQ was established in the
same way as LOD, except that the S/N ratio was about 10.
The LOD of this method for L and C forms were 0.08 µg/
mL (% R.S.D. = 6.58) and 0.02 µg/mL (% R.S.D. = 3.61),
respectively. The LOQ of this method for L and C forms
were 0.26 µg/mL (% R.S.D. = 2.24), and 0.12 µg/mL (%
R.S.D. = 1.92), respectively.

The robustness of the method was investigated
under a variety of conditions, including changes of pH
of the eluent, ﬂow rate, column temperature, and ratio
(acetonitrile to buffer solution) of the mobile phase (25).
The degree of reproducibility of the results obtained as a
result of small deliberate variations in the method parameters and analytical operators has proven that the method
is robust (Table 4).
Overall, the method demonstrated sufficient robustness and suitability for the analysis of SN-38 NPs under
the deliberately altered HPLC conditions.

(V) Linearity and Range (Calibration Curve)

(VII) System Suitability Test

Linearity was established by least squares linear
regression analysis of the calibration curve (25). As in this
study the concentration of test solution was 40 µg/mL,
so the Analytical Validation Standard Solution (AVSS)
covered from 10 to 250% of assay concentration (4 to 100
µg/mL, n = 7) seems suitable for determination of SN-38
loaded PLGA NPs. Peak areas of SN-38 were plotted
versus their respective concentrations and linear regression analysis performed on the resultant curves. The
mobile phase was filtered through a 0.45-µm membrane

System suitability tests are an integral part of liquid
chromatographic methods. They are used to verify that
resolution and reproducibility of the chromatographic
system are adequate for the analysis (21). On the basis our
analytical validation results, the values for column efficiency (N), tailing factor (T), resolution (R), and RSD
(%) were calculated. The column efficiency was more
than 1000 theoretical plates for SN-38 L and C forms.
The tailing factor, T, a measure of peak symmetry was
determined as 1.01 for both forms which is less than usual

Table 4. Robustness of the method by changing the experimental parameters on the performance of chromatographic system
Variable Parameters

Buffer composition* (v/v)

pH of mobile phase

Flow rate (mL/min)

Temperature (°C)

Modification

Recovery (%)
for L form

30:34:36

100.02

30:30:40

100.3

30:26:44

99.7

2.7

99.25

3

100.6

3.3

98.9

98.9

0.9

99.8

97.9

1

98.9

1.1

100.2

27

101.02

30

99.6

33

100.4

The concentration of the solution analyzed was 40 µg/mL.
*: Ion-pair solution, solution B and acetonitrile

RSD (%)
for L form

Recovery (%)
for C form

RSD (%)
for C form

98.8
0.30

100.1

0.68

99.1
101.04
0.90

0.66

100.3

99.1

1.07

0.84

99.5
0.70

100.7
101.1 99.7

0.71
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(VIII) Stability of Drug Solution
The three-day percentage relative standard deviation
of the retention time and (%) recovery of SN-38 C and L
forms was less than 1% (Table 5). No significant degradation was observed within three days, indicating that SN38 C and L forms solutions were stable for at least three
days at room temperature.
III. Application of the Method
The proposed method was applied to study SN-38
association with PLGA NPs produced by modified emulsification solvent evaporation method. Previous experiments were done to establish the ideal formulation and
to characterize those NPs. The encapsulation efficiency (EE) of SN-38 NPs was more than 80% due to high
lipophylicity of SN-38. No SN-38 C peak was detected
in SN-38 loaded PLGA NPs. The EE was also evaluated
during the shelf life in order to assess the SN-38 stability associated with the carriers. The EE did not change
after 6 month of storage at 4°C. It was demonstrated that
no other NP components interfered with SN-38 determination. Figure 6 shows the profile of SN-38 release from

the NPs in PBS (pH 7.4) as a suitable application of this
method. SN-38 release was characterized by an immediate burst effect. Up to 10% of SN-38 was released from
NPs within 1day of contact with the release media and a
cumulative release of 35% occurred after 10 days. This
was expected because of its highly hydrophobic nature
which prevented the drug diffusion from the polymer
matrix into the aqueous solution. We also applied this
validated HPLC method to determine pharmacokinetic of
SN-38-loaded PLGA NPs in rat plasma (data not shown).
HPLC analysis in the in vitro release test confirmed that
the release drug had the same retention time as the free
SN38, indicating that the chemical structure of SN38 was
not damaged during NP preparation. Nevertheless, to
further verify whether the released SN38 was still pharmacologically active and to evaluate the potential cytotoxicity of SN38-free drug and SN-38 NPs, an in vitro

Cumulative Release (%)

pharmacopoeial standard (less than 2.0). The relative
standard deviation for replicate injections was also less
than 2.0%. The resolution, R, was specified to ensure that
closely eluting compounds are resolved from each other
to establish the general resolving power of the system. As
shown in Figure 3, the resolution for L and C forms of
SN-38 is 5.86 ± 0.12 (n = 3).
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Figure 6. In vitro release curve of SN-38 loaded PLGA nanoparticles
using the proposed HPLC method.

Table 5. Stability study of SN-38 solution
L form
Day

Concentration
(µg/mL)

RSD of
tR (%)

Recovery
(%)

RSD
(%)

Recovery
(%)

RSD
(%)

99.7, 101.0, 100.1

0.66

100.01, 98.2, 98.7

0.93

100.2, 99.1, 98.5

0.86

98.5, 99.8, 99

0.65

100

100.1, 98.7, 100.5

0.95

101, 99.6, 99.5

0.83

4

100.2, 99.8, 100.6

0.40

99.2, 98.7, 98.1

0.55

99.9, 100.1, 101.7

0.98

98.8, 100.1, 99

0.70

100

100.1, 98.7, 98.9

0.76

100, 99.1, 98.8

0.62

4

100.2, 99.4, 98.9

0.65

97.9, 98.6, 99

0.56

98.6, 99.2, 98.1

0.56

98.7, 99.1, 99.3

0.30

98.2, 99.1, 98.7

0.46

99.2, 8.05,100.01

0.98

4
1

2

3

40

40

40
100

n=3

C form

0.11

0.29

0.48

RSD of
tR (%)

0.52

0.59

0.64
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cytotoxicity test against HT29 cells (as a colon carcinoma
cell lines) was performed. The obtained results confirmed
that SN-38 loaded PLGA NPs were more cytotoxic than
SN38-free drug (data not shown).

CONCLUSIONS
This study has described a new, rapid and validated ion-pair RP-HPLC method for simultaneous determination of L and C forms of SN-38 according to the
ICH guidelines. All parameters were within the limits
proposed by the guidelines for pharmaceutical formulations, indicating that this method is speciﬁc, precise,
accurate and robust with low detection and quantitation limits. Furthermore, suitable application for SN38 in vitro analysis can be assumed during formulation
development and characterization. The proposed method
was used to predict the encapsulation efficiency, release
profile, cytotoxicity and biodistribution study of SN-38
from nanoparticulate carriers.
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